University of Ljubljana   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ljubljana Slovenia (1919)

Organization Overview

First Clinical Trial
2002
NCT01243632
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Advanced Heart Failure and Transplantation Center, Universtiy Medical Center Ljubljana, Slovenia | Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia | Brachytherapy Department, Institute of Oncology Ljubljana, Slovenia | CD of Anaesthesiology and Intensive Therapy, University Medical Centre Ljubljan | CD of Anaesthesiology and Intensive Therapy, University Medical Centre Ljubljana | CD of Neurosurgery, University Medical Centre Ljubljana | CLINICAL INSTITUTE OF CLINICAL CHEMISTRY AND BIOCHEMISTRY, University Medical Centre Ljubljana | David Drobne | Department of Endocrinology, Diabetes and Metabolic Diseases, Medical Center Ljubljana, Zaloska 7, 1525 Ljubljana, Slovenia | Department of Gynecology, Division of Gynecology and Obstetrics, Ljubljana University Medical Center | Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia | Department of Infectious Diseases, University Medical Centre Ljubljana, Slovenia | Department of Oral Medicine and Periodontology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia | Department of Otorhinolaryngology and Cervicofacial Surgery, UMC Ljubljana | Dep. of Cardiology, Uni. Medical Center Ljubljana, Slovenia | Dept. of Medical Oncology, Institute of Oncology Ljubljana, Slovenia | Dept. of Psychiatry and Psychotherapy; TU Dresden | Dept. of Radiation Oncology, Institute of Oncology Ljubljana, Slovenia | Division of Ob/Gyn, University Medical Centre Ljubljana, Slovenia | Dr Adolf Lukanovič | Faculty of Natural Science and Engineering, University of Ljubljana | General Hospital Murska Sobota; University of Ljubljana, Faculty of Medicine | General Hospital Murska Sobota; University of Ljubljana, Faculty of Sport | Institute of microbiology and immunology, Ljubljana, Slovenia | Institute of microbiology and immunology, Slovenia | Institute of mircobiology and immunology, Slovenia | Institute of Oncology Ljubljana | Institute of Oncology Ljubljana, Department of Surgical Oncology, Ljubljana, Slovenia | Institute of Oncology Ljubljana, Ljubljana, Slovenia | Institute of Oncology Ljubljana, Slovenia | Institute of Oncology, Ljubljana, Slovenia | Institute of Pharmacology and Experimental Toxicology, Medical Faculty, University Ljubljana | JKastrup | Ljubljana University | Marija Malgaj | UCMLjubljana | UMC Ljubljana | UMC LJUBLJANA | UMC Ljubljana, Department of Infectious Diseases Ljubljana, Slovenia | UMCLjubljana, KOAIT | UMC Ljubljana Slovenia | University Eye Clinic Ljubljana | University Medical center, Hypertension Department - Ljubljana (Slovenia) | University Medical Center Ljubljana, Department of Gastroenterology | University Medical Center Ljubljana, Slovenia | University Medical Centre Ljubljana | University Medical Centre Ljubljana, Department of Nephrology | University Medical Centre Ljubljana, Department of Vascular Disease | University Medical Centre Ljubljana, Ljubljana, Slovenia | University Medical Centre Ljubljana (Slovenia) | University Medical Centre Ljubljana, Slovenia | University of Ljubljana | University of Ljubljana, Faculty of Medicine | University of Ljubljana, Faculty of Medicine, Institute of Pharmacology and Experimental Toxicology | University of Ljubljana, Faculty of Pharmacy | University of Ljubljana School of Medicine | University of Ljubljana School of Medicine, Slovenia

Active Ingredients

Drugs in Phase 4 Trials (42)

amlodipine (norvasc) (1 trial)

cangrelor (kengreal) (1 trial)

cefuroxime (zinacef) (3 trials)

clavulanate (Augmentin) (1 trial)

clopidogrel (plavix) (1 trial)

corifollitropin alfa (1 trial)

dalteparin (fragmin) (1 trial)

denosumab (prolia) (1 trial)

dexmedetomidine (precedex) (4 trials)

dinoprostone (prostin e2) (1 trial)

dorzolamide (trusopt) (1 trial)

doxycycline (vibramycin) (14 trials)

empagliflozin (jardiance) (1 trial)

ezetimibe (zetia) (1 trial)

fentanyl (Innovar) (2 trials)

golimumab (simponi) (1 trial)

indapamide (lozol) (1 trial)

lactobacillus reuteri (3 trials)

latanoprost (xalatan) (1 trial)

l-glutamine (1 trial)

lidocaine (xylocaine) (1 trial)

liraglutide (victoza) (8 trials)

metformin (glucophage) (2 trials)

mk-0524 (1 trial)

mycophenolate (myfortic) (1 trial)

niacin (1 trial)

perindopril (aceon) (1 trial)

procaine benzylpenicillin (novocaine) (4 trials)

propofol (diprivan) (3 trials)

roflumilast (daliresp) (2 trials)

semaglutide (Ozempic) (2 trials)

sitagliptin (januvia) (10 trials)

sodium citrate (2 trials)

testosterone (delatestryl) (2 trials)

thiamine (1 trial)

ticagrelor (brilinta) (1 trial)

timolol (blocadren) (1 trial)

unfractionated heparin (3 trials)

urea (1 trial)

vipdomet (1 trial)

vitamin c (3 trials)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 3 Trials (11)

chlorhexidine (hibitane) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

ferrous sulfate (1 trial)

iron isomaltoside (1 trial)

methylprednisolone (medrol) (1 trial)

paricalcitol (zemplar) (1 trial)

piritramide (1 trial)

platelet rich plasma (2 trials)

ropivacaine (naropin) (1 trial)

sodium chloride (1 trial)

stem cells (1 trial)

Drugs in Phase 2 Trials (16)

allogeneic adipose derived mesenchymal stem cell (1 trial)

autologous cd34+ cells (1 trial)

bevacizumab (avastin) (1 trial)

bleomycin (blenoxane) (3 trials)

bone marrow derived mesenchymal stem cells (1 trial)

capecitabine (xeloda) (5 trials)

cetuximab (erbitux) (3 trials)

cisplatin (platinol) (4 trials)

docetaxel (taxotere) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

letermovir (prevymis) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

ranolazine (ranexa) (1 trial)

rostafuroxin (1 trial)

Drugs in Phase 1 Trials (5)

111in-cp04 (1 trial)

gelofusin (1 trial)

phil12 (1 trial)

sevoflurane (ultane) (2 trials)

zolpidem (ambien) (1 trial)

Drugs in Other Trials (45)

acetylcysteine (mucomyst) (1 trial)

aciclovir (zovirax) (1 trial)

alirocumab (praluent) (1 trial)

amoxicillin (1 trial)

astaxanthin (1 trial)

autologous mononuclear stem cell (1 trial)

autologous stromal vascular fraction (1 trial)

beta-glucans (1 trial)

betamethasone (celestone) (1 trial)

blood plasma (2 trials)

caffeine (1 trial)

cannabis (1 trial)

carbetocin (1 trial)

carbon dioxide (dry ice) (1 trial)

carboplatin (paraplatin) (1 trial)

ceftriaxone (rocephin) (4 trials)

clarithromycin (biaxin) (2 trials)

clonidine (catapres) (1 trial)

ethanol (1 trial)

eukalyptol (1 trial)

evolocumab (repatha) (1 trial)

fibrinogen (human) (RiaSTAP) (1 trial)

fluvastatin (lescol) (2 trials)

gentamicin (garamycin) (1 trial)

hydroxyethyl starch (1 trial)

insulin aspart (novolog) (1 trial)

insulin human (humulin) (1 trial)

ionis-apo(a)-lrx (1 trial)

levobupivacaine (chirocaine) (3 trials)

lithium (lithonate) (1 trial)

melatonin (1 trial)

menthol (Salonpas) (1 trial)

methyl salicylate (1 trial)

metronidazole (flagyl) (3 trials)

ondansetron (zofran) (1 trial)

oseltamivir (tamiflu) (1 trial)

oxytocin (syntocinon) (1 trial)

progesterone (progestasert) (1 trial)

remifentanil (ultiva) (1 trial)

sterofundin (1 trial)

tetracycline (tetrex) (1 trial)

thymol (1 trial)

trisodium citrate (1 trial)

valsartan (diovan) (2 trials)

vitamin e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Albuminuria (Phase 3)

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Body Weight (Phase 4)

Carcinoma (Phase 1)

Carcinoma, Neuroendocrine (Phase 1)

Cardiomyopathies (Phase 3)

Cardiomyopathy, Dilated (Phase 3)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Communicable Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Critical Illness (Phase 4)

Diabetes Complications (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Dysgeusia (Phase 4)

Dyslipidemias (Phase 4)

Dystonia (Phase 1)

Dystonic Disorders (Phase 1)

Erythema (Phase 4)

Erythema Chronicum Migrans (Phase 4)

Essential Hypertension (Phase 2)

Eunuchism (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Glossitis, Benign Migratory (Phase 4)

Glucose Intolerance (Phase 4)

Head and Neck Neoplasms (Phase 2)

Heart Arrest (Phase 4)

Heart Diseases (Phase 4)

Helicobacter Infections (Phase 4)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Primary (Phase 4)

Hypertension (Phase 4)

Hypogonadism (Phase 4)

Infarction (Phase 4)

Infections (Phase 4)

Infertility (Phase 4)

Infertility, Female (Phase 4)

Inflammation (Phase 1)

Insulin Resistance (Phase 4)

Liver Neoplasms (Phase 2)

Lyme Disease (Phase 4)

Mesothelioma (Phase 2)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Neuralgia (Phase 4)

Non-ST Elevated Myocardial Infarction (Phase 4)

Obesity (Phase 4)

Ocular Hypertension (Phase 4)

Opioid-Related Disorders (Phase 4)

Osteoporosis (Phase 4)

Out-of-Hospital Cardiac Arrest (Phase 4)

Pain, Postoperative (Phase 3)

Polycystic Ovary Syndrome (Phase 4)

Pre-Eclampsia (Phase 1)

Proteinuria (Phase 3)

Rectal Neoplasms (Phase 2)

Renal Insufficiency (Phase 4)

Sepsis (Phase 4)

Shock (Phase 4)

Shock, Septic (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Thrombophlebitis (Phase 4)

Thrombosis (Phase 4)

Thyroid Diseases (Phase 1)

Thyroid Neoplasms (Phase 1)

Toxemia (Phase 4)

Ulcer (Phase 4)

Venous Thrombosis (Phase 4)

Weight Loss (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 121
  • # of Trial APIs: 119